The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 103.00
Bid: 102.00
Ask: 104.00
Change: 0.00 (0.00%)
Spread: 2.00 (1.961%)
Open: 103.00
High: 103.00
Low: 103.00
Prev. Close: 103.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Shareholding/Share Incentive Plan

1 Sep 2021 07:00

RNS Number : 3003K
Diaceutics PLC
01 September 2021
 

 

1 September 2021

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

PDMR Shareholding/Share Incentive Plan

 

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified that on 27 August 2021 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted and Damian Thornton (both PDMRs), in respect of their purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

 

In accordance with the SIP Scheme, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.

 

 

Enquiries:

 

Diaceutics PLC 

 

Philip White, Chief Financial Officer 

Via Alma PR 

 

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison

 

Stewart Wallace

 

Nick Adams

 

 

 

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Robyn Fisher

 

Kieran Breheny

 

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

a.

Position/Status

Managing Director and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

113.00 p

126

Conditional share award:

Price(s)

Volume(s)

Nil

252

e.

Date of the transaction

Share purchase and Conditional share award: 27 August 2021

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Conditional share award: Off-Market

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Damian Thornton

2

Reason for notification

a.

Position/Status

Chief Operating Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares to matched by the grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

113.00 p

130

Options:

Price(s)

Volume(s)

Nil

260

 

 

e.

Date of the transaction

Share purchase and Option award: 27 August 2021

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Option award: Off-Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKDBQFBKDPFN
Date   Source Headline
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR
27th Feb 20247:00 amRNSExpanded lab network and data capabilities
14th Feb 20241:00 pmRNSDiaceutics PLC - Strategic alliance with KPMG
5th Feb 20247:00 amRNSAppointment of VP, Scientific & Medical Services
1st Feb 202412:31 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Jan 20247:00 amRNSDiaceutics PLC – Trading Update
25th Jan 20241:16 pmRNSExercise of Warrant & Total Voting Rights
19th Jan 20247:00 amRNSDiaceutics PLC – Financial Calendar Update
29th Dec 20231:18 pmRNSPDMR Shareholding/Share Incentive Plan
30th Nov 202312:59 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Nov 20237:00 amRNSDiaceutics to attend Stifel Conference in NYC
21st Nov 202311:13 amRNSNotification of Major Holdings
31st Oct 202312:38 pmRNSPDMR Shareholding/SIP & Total Voting Rights
11th Oct 20231:47 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
2nd Oct 20233:59 pmRNSBlock Listing Application to AIM
29th Sep 202311:19 amRNSHolding(s) in Company
26th Sep 20237:00 amRNSDiaceutics PLC – Half Year Results
26th Sep 20237:00 amRNSDiaceutics PLC - Planned CEO Transition
21st Sep 20232:37 pmRNSDiaceutics PLC – Directorate Changes
7th Sep 20237:00 amRNSAttending 10th Annual HealthTech Investment Forum
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
30th Aug 20232:56 pmRNSPDMR Shareholding/Share Incentive Plan
29th Aug 20237:00 amRNSDiaceutics launches daily alerts for DXRX platform
4th Aug 20237:00 amRNSCanaccord Genuity 43rd Annual Growth Conference
31st Jul 20233:19 pmRNSPDMR Shareholding/Share Incentive Plan
25th Jul 20237:00 amRNSTrading Update and Notice of Results
29th Jun 202312:07 pmRNSPDMR Shareholding/Share Incentive Plan
6th Jun 20237:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
5th Jun 20237:00 amRNSUSD 10.1 million multi-year enterprise engagement
31st May 20235:13 pmRNSPDMR Shareholding/Share Incentive Plan
19th May 202310:16 amRNSIssue of Share Options/PDMR Shareholdings
18th May 202311:46 amRNSResults of Annual General Meeting
11th May 20236:22 pmRNSPDMR Shareholdings
4th May 202310:34 amRNSPDMR shareholdings
28th Apr 20236:03 pmRNSPDMR Shareholding/Share Incentive Plan
26th Apr 20235:03 pmRNSPDMR Shareholding
25th Apr 20235:45 pmRNSNotice of AGM and Posting of Annual Report
17th Apr 20237:00 amRNSFinal Results
3rd Apr 20232:43 pmRNSPDMR Shareholding / Share Incentive Plan
20th Mar 20237:00 amRNSNotice of Results and Presentations
13th Mar 202310:15 amRNSRestoration - Diaceutics PLC
13th Mar 202310:12 amRNSFurther update regarding Silicon Valley Bank
13th Mar 20237:30 amRNSSuspension - Diaceutics PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.